Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Vaginitis Treatment Drugs Market Players Need to Focus on Reinfection Prevention, Concludes Future Market Insights

This image opens in the lightbox

News provided by

Future Market Insights

07 Jul, 2020, 13:01 GMT

Share this article

Share toX

Share this article

Share toX

DUBAI, U.A.E, July 7, 2020 /PRNewswire/ -- Future Market Insight's latest report on the vaginitis treatment drugs market establishes that growth is anticipated to be positive, registering a CAGR of 5% between 2020 and 2030.

It has been discovered that vaginal infections plague two-fifths of the women population across the world. Vaginitis can lead to serious complications and risks such as miscarriage, pre-mature births and HIV-AIDS if left untreated. Other diseases such as gonorrhea, chlamydia and papillomavirus are also known to occur as potential complications. A key problem in detecting vaginitis is that a majority of the patients are asymptomatic. This leads to difficulties in prescribing appropriate medications.

The abovementioned trends have therefore made it a top priority for healthcare players to accelerate research in the detection, diagnosis and treatment of vaginitis infections. One of these approaches is developing appropriate drug formulations, which have witnessed a major upsurge in the past few years. Constant innovations in treatment are being discovered, placing the market on a higher pedestal in the forecast period.

"The vaginitis treatment drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate. Players are introducing single-dose and over-the-counter drugs which provide cost effective treatment," infers an FMI analyst.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-11790

Key Takeaways from FMI's Vaginitis Treatment Drugs Report

  • Vaginitis treatment drugs market is slated to reach a valuation of ~US$ 3 Bn by the end of 2020
  • Nitro Imidazole compounds are the largest revenue generators by drug type, registering a revenue share of 44% across the forecast period
  • By schedule, prescription drugs dominate the vaginitis treatment drugs market, contributing 75% of the market value
  • Growing recurrence of bacterial vaginosis and complicated vulvovaginal candidiasis (VVC) remains a principal growth accelerator

Vaginitis Treatment Drugs Market- Key Trends

  • Online pharmacies account for maximum transactions of vaginitis treatment drugs. The outbreak of the coronavirus pandemic has accelerated usage of online retail outlets in order to minimize the risk of exposure to the virus when visiting an actual pharmacy
  • At least half of the women with bacterial vaginosis are asymptomatic. As a result, treatment gets delayed and complications keep compounding. This has spurred market players to accelerate innovations making it possible to detect asymptomatic cases

Vaginitis Treatment Drugs Market- Region-wise Analysis

  • Europe's vaginitis treatment drugs market accounts for a quarter of the global vaginitis treatment drugs market. Increased supply of vaginal tablets in pharmacies is stimulating market growth
  • North America remains the most lucrative market, with the United States capturing the leading share. A higher rate of over the counter medicine availability is providing impetus for further growth
  • South Africa and Brazil also represent credible opportunities as both are developing nations with a high incidence of vaginal infections

Vaginitis Treatment Drugs Market- Competitive Landscape

The vaginitis treatment drugs market is experiencing an influx of novel drugs. A number of clinical trials, drug development projects, establishment of distribution channels and e-commerce platforms are being witnessed. The market is highly consolidated, with over 25 players capturing a major chunk of the market.

The market players are incorporating nitro imidazole, tinidazole and metronidazole compounds in their formulations to manufacture vaginitis drugs. They are also concentration on strategic collaborations to introduce new drugs, such as the one between Basilea Pharmaceutica Ltd and Pfizer Inc in December 2017. The two giants collaborated to develop and commercialize Cresemba, an isavuconazole-based drug in the Asia-Pacific region.

Recently, Plush Care collaborated with Lupin Pharmaceuticals to facilitate bacterial vaginosis treatment through the former's virtual care platform. This enables patients to virtually seek appointments with doctors, discuss the symptoms and get prescribed for lab testing.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/customization-available/rep-gb-11790

Vaginitis Treatment Drugs Market Taxonomy

Drug Type

  • Nitro Imidazole Compounds
  • Lincosamide Antibiotics
  • Triazoles
  • Imidazoles

Indication

  • Bacterial Vaginitis
  • Fungal Vaginitis (Yeast Infection)
  • Trichomoniasis

Route of Administration

  • Oral
  • Cutaneous
  • Vaginal

Schedule of Drug

  • Prescription Drugs (Rx)
  • Over-the-Counter Drugs (OTC)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies

Region/Country

North America

  • U.S
  • Canada

Latin America

  • Mexico
  • Brazil
  • Others

Europe

  • EU-5
  • Nordic countries
  • BENELUX
  • Poland
  • Russia

South Asia

  • India
  • ASEAN

East Asia

  • China
  • Japan
  • South Korea

Oceania

  • Australia
  • New Zealand

MEA

  • GCC
  • Southern Africa
  • Northern Africa

COVID -19: Impact Analysis@ https://www.futuremarketinsights.com/covid19/rep-gb-11790

More Insights on the Vaginitis Treatment Drugs Market

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global Vaginitis Treatment Drugs Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on Vaginitis Treatment Drugs Market on basis of drug type (nitroimidazole compound, lincosamide antibiotics, triazoles, imidazoles), indication (bacterial vaginitis, fungal vaginitis (yeast infection), trichomoniasis), route of administration (oral, cutaneous, vaginal), schedule of drug (prescription drugs (Rx), over-the-counter drugs (OTC)) distribution channels (hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies) across seven major regions.

Explore Extensive Coverage on FMI's Healthcare, Pharmaceuticals and Medical Devices Market

Candida Vaginitis Rapid Testing Market: FMI's ongoing research project on the candida vaginitis rapid testing market offers comprehensive analysis of the business models, key strategies and respective market shares of some of the most prominent players in the competition landscape. It also offers insights regarding prominent dynamics influencing the growth of the market.

Women's Health Diagnostic Testing Market: The women's health diagnostic testing market study-in-progress establishes that the market is set to broaden in scope throughout the forecast period until 2027. The market is segmented based on application type and end-user across prominent regions.

Cervical Implants Market: The cervical implants market report offers a comprehensive analysis of prominent drivers, opportunities and restraints associated with the growth of the market across various segments in seven prominent regions. 

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com 
For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/vaginitis-treatment-drugs-market

Press Release Source: https://www.futuremarketinsights.com/press-release/vaginitis-treatment-drugs-market

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg

Modal title

Also from this source

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

The isoprene rubber latex industry is predicted to be valued at USD 922 million by 2024. The market valuation is estimated to be USD 2,005.3 million...

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

According to Future Market Insights (FMI), the global mezcal market demand is estimated to reach a valuation of USD 635 million by 2024. Over the...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.